←
Caribou Biosciences617 posts
Caribou Biosciences avatar

Caribou Biosciences

@CaribouBio

Clinical-stage biopharmaceutical company developing transformative therapies to treat devastating human diseases

◷ Joined July 2014▧ 395 Photos and videos
Caribou Biosciences avatar
Caribou Biosciences@CaribouBio·Oct 6

We have made the difficult decision to evaluate strategic alternatives and discontinue our allogeneic CAR-T cell therapy programs due to challenges securing necessary capital to responsibly advance these programs. Read more: bit.ly/47506ys $CRBU

0:11
Caribou Biosciences avatar
Caribou Biosciences@CaribouBio·Sep 28

We’re a finalist for @Citeline’s 2026 Best Oncology R&D Advance Award! This recognition serves as a testament to the potential of vispa-cel, our pivotal-ready allogeneic CAR-T cell therapy, to expand access for patients. See all the finalists: bit.ly/4hitrLL $CRBU

Post attachment
Caribou Biosciences avatar
Caribou Biosciences@CaribouBio·Jul 28

For patients facing relapsed or refractory #lymphoma, timely access to treatment can be critical. Watch Dr. Mehdi Hamadani share his perspective on treatment decisions and the value of an off-the-shelf option. Watch the full video here: bit.ly/44JKhw0 #CellTherapy

1:07
Caribou Biosciences avatar
Caribou Biosciences@CaribouBio·Jul 22

#ICYMI @MM_Hub published an interview with Dr. Binod Dhakal about the CB-011 data at #EHA2026. Watch below to hear about the potential for this single-dose, off-the-shelf approach to help broaden CAR-T cell treatment access. #CellTherapy #CRISPR $CRBU

Binod Dhakal discusses the latest findings from the phase I CaMMouflage trial evaluating CB-011 in patients with RRMM, presented at #EHA2026. shows.acast.com/mm-hub #mmsm #myeloma #MedEd #MedNews #MedicalCongress @bhemato

Post attachment
Caribou Biosciences avatar
Caribou Biosciences@CaribouBio·Jul 16

#ICYMI @lymphomahub’s interview with Dr. Stephen Schuster is live, discussing the vispa-cel data presented at #EHA2026 that demonstrate durable, auto-CAR-T-like responses from a single, off-the-shelf dose. Listen below. #CellTherapy #CRISPR $CRBU

Stephen Schuster discusses the latest findings from the phase I ANTLER trial, presented at #EHA2026, evaluating vispa-cel in R/R B-cell NHL. Listen here: bit.ly/4oVAA6K #lymsm #MedEd #MedNews #MedicalCongress

Post attachment
Caribou Biosciences avatar
Caribou Biosciences@CaribouBio·Jul 13

#ICYMI Dr. Binod Dhakal spoke with @MyelomaEurope about the CB-011 data presented at #EHA2026 and what it means for patients. Check out the full interview below. #CellTherapy #CRISPR $CRBU

At #EHA2026, Dr Binod Dhakal (Medical College of Wisconsin) spoke to MPE about the CaMMouflage trial, a phase 1 study of CB-011, an allogeneic anti-BCMA CAR T-cell therapy in relapsed/refractory myeloma. Watch now: youtu.be/NTMTfENCq5Q #Myeloma #CART #MyelomaPatientsEurope

Caribou Biosciences avatar
Caribou Biosciences@CaribouBio·Jun 24

The excitement at #BIO2026 continues! Join Rachel Haurwitz, PhD, President & CEO, and a panel of experts as they dive into what the next decade of biotech looks like to help support patients. Learn more about the session: bit.ly/4eBR0MJ

Post attachment